Why does it take so long for new therapies to emerge from basic research? This is a question that researchers at the MDC and beyond encounter frequently. For us it was also the starting point for a film – and food for thought about the value of basic research.
A Berlin study of patients with early-stage colon cancer shows that DNA repair mechanisms and MACC1 gene activity helps determine prognosis and predict response to chemotherapy.
A new study in the journal Nature reveals that a small signaling molecule has the ability to cut off the blood supply to tumors. This allows the immune system’s T-cells to indirectly fight cancer.
B cells require surface molecules called B cell receptors to survive. Most tumor cells that arise from B cells seem to need them as well, but rare exceptions may escape therapies. After 15 years, scientists finally understand why.
The signaling molecule interferon gamma is produced by T-cells and it plays a key role in T-cell therapy. It cuts off the blood supply to tumors, as a new study in the journal Nature reveals.
Researchers at the MDC have developed antibodies that promise to heal multiple myeloma. The biotechnology company Heidelberg Pharma will now develop one of these antibodies to an antibody-toxin agent and test it clinically at the end of 2018.
Dr. Matthias Leisegang is the recipient of this year’s Curt Meyer Memorial Prize for his research work into analysing cancer mutations as a target in adoptive T-cell therapy. His work will allow the development of a patient-specific immunotherapy that fights cancer in a targeted way.
Dr. Roland F. Schwarz of the MDC conducts research on tumors using bioinformatics. He has just been awarded the Prize of the Berlin-Brandenburg Academy of Sciences and Humanities (BBAW), donated by the Monika Kutzner Foundation for the Advancement of Cancer Research, for his outstanding work.
Bioinformatician Roland Schwarz has been lead investigator of the new BIMSB junior research group on “Evolutionary and Cancer Genomics” since October 2016. Schwarz wants his work, particularly in the area of cancer research, to contribute towards ensuring that diseases are diagnosed earlier and treated more effectively.
Protein Kinase A (PKA) is a protein that enjoys enough fame to be sketched by young biochemists listening to lectures about how it is regulated. The fundamental kinase is present throughout the body with a role in countless processes. It’s easy to think PKA is so well studied that we know everything about it, but scientists at the MDC have found a new layer of PKA regulation which was published this week in Nature Communications.